The vendor-published certificate of analysis, assessed as evidence

Every purchase in this category rests on a document that most buyers skim. The certificate of analysis is treated as a formality — a PDF to be downloaded, glanced at for a percentage, and filed. It is worth assessing properly, because what it establishes is narrower than what it is routinely taken to establish.

We are assessing a document type, not a supplier. The question is what a typical vendor-published COA proves about the vial in your hand.

What the document contains

That list looks comprehensive. Read it again as a buyer, and the gaps become visible.

What it establishes

A well-formed COA establishes three things, and does so genuinely well.

It establishes identity — that the material analysed was what the label says, within the confidence of the method used. Mass spectrometry answering to the expected molecular weight is meaningful evidence, and a supplier who publishes the spectrum rather than a one-line result is offering something a reader can check.

It establishes a purity figure for the sample analysed. The chromatogram, where published, is the substantive part. A percentage on its own is a conclusion; a chromatogram is the working. Suppliers who publish the trace are letting you see peak shape and anything eluting alongside the main peak, which a summary figure conceals.

It establishes a point in time. The date of analysis is the anchor for everything else on the page, and it is the field most often skipped.

What it does not establish

Here the document is weaker than its reputation.

It does not establish that your vial came from the analysed lot. This is the central limitation. The report characterises a sample. The link between that sample and the vial delivered to you is the lot number, and the lot number is only as good as the labelling practice behind it. Where a vendor publishes one report per product rather than one per lot, that link does not exist at all — the document is a specimen, not a record.

It does not establish stability since analysis. Purity is measured once. Material is stored and shipped afterwards. The COA is silent on everything that happened in between, which is why storage and shipping documentation is a separate question and not a subordinate one.

It does not establish independence unless it says so. An in-house report and a third-party report look near-identical in layout. The analysing party is a field on the page, and if it is absent, the safe assumption is that the seller analysed its own material.

It does not establish what is absent. A purity figure describes the main peak. It does not enumerate what constitutes the remainder, and residual solvents, counter-ions and water content are frequently outside the scope of the report entirely.

Reading one properly

The check takes two minutes. Match the lot number on the vial to the lot number on the report — if they do not match, or if the report carries no lot number, you have a specimen document. Read the date. Identify the analysing laboratory, and note whether the supplier names it or merely alludes to one. Then look for the chromatogram: its presence is the single best proxy for whether a supplier expects the document to be read.

Everything on such a report concerns composition. It says nothing about fitness for any use in humans, and it is not intended to — these materials are supplied for laboratory research use only.

Pros and cons

Verdict

The COA is the best document this market produces and it is still a partial one. Our position is that a buyer should treat it as establishing identity and a historical purity figure — nothing further — and should treat per-lot publication, a named analysing laboratory and a visible chromatogram as the three features that separate a record from a marketing asset. Where all three are present, the paperwork is doing its job. Where none are, the percentage on the page is a number the seller chose to print.